GALLIUM Trial: GAZYVA vs rituximab in Previously Untreated FL 1

With chemotherapy* for stage II bulky, III, and IV patients

This Phase III, randomized trial was designed to answer one primary question: In patients with previously untreated FL, did the GAZYVA based regimen deliver superior PFS compared with the rituximab-based regimen? 1

  • Primary endpoint: PFS as assessed by Independent Review Committee (IRC)
  • Additional endpoints: Response rates at end of induction (IRC-assessed, assessed by CT ± PET), PFS by chemotherapy regimen (IRC-assessed)

GAZYVA WAS STUDIED IN A TRIAL OF OVER 1,200 PATIENTS WITH PREVIOUSLY UNTREATED FL 1

With chemotherapy* for stage II bulky, III, and IV patients

GALLIUM evaluated GAZYVA vs rituximab when each was combined with bendamustine, CHOP, or CVP and followed by GAZYVA or rituximab monotherapy, respectively

The GAZYVA and rituximab arms were generally well balanced with respect to demographic factors and baseline disease characteristics6